Breast cancer predisposition syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 5, 2010, Pages 799-814

  Hemel, Deborah ^a   Domchek, Susan M ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA1; BRCA2; Cowden Syndrome; Hereditary Breast and Ovarian Cancer Syndrome; Li Fraumeni Syndrome; PTEN; TP53

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN P53; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE;

BREAST CANCER; BREAST EXAMINATION; BREAST HAMARTOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COWDEN SYNDROME; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MAMMOGRAPHY; MASTECTOMY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVARY CANCER; PENETRANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SECOND CANCER; TREATMENT RESPONSE;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PENETRANCE; PRACTICE GUIDELINES AS TOPIC; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956324506     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.06.004     Document Type: Review

References (85)

1. US Preventive Services Task Force Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151(10):716-726.
2. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48(18):5358-5362.
3. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250(4985):1233-1238.
4. Gonzalez K.D., Noltner K.A., Buzin C.H., et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27(8):1250-1256.
5. Frebourg T., Barbier N., Yan Y.X., et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995, 56(3):608-615.
6. Varley J.M., McGown G., Thorncraft M., et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997, 57(15):3245-3252.
7. Birch J.M., Hartley A.L., Tricker K.J., et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54(5):1298-1304.
8. Eeles R.A. Germline mutations in the TP53 gene. Cancer Surv 1995, 25:101-124.
9. Rapakko K., Allinen M., Syrjakoski K., et al. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 2001, 84(1):116-119.
10. Gonzalez K.D., Buzin C.H., Noltner K.A., et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 2009, 46(10):689-693.
11. Achatz M.I., Hainaut P., Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?. Lancet Oncol 2009, 10(9):920-925.
12. Evans D.G., Birch J.M., Thorneycroft M., et al. Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet 2002, 39(12):941-944.
13. Borresen A.L., Andersen T.I., Garber J., et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992, 52(11):3234-3236.
14. Hwang S.J., Lozano G., Amos C.I., et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003, 72(4):975-983.
15. Kleihues P., Schauble B., zur Hausen A., et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997, 150(1):1-13.
16. Lalloo F., Varley J., Moran A., et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006, 42(8):1143-1150.
17. NCCN clinical practice guidelines in oncology-genetic/familial high-risk assessment: breast and ovarian. 2009 Available at:, Accessed December 26, 2009. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf.
18. Masciari S., Van den Abbeele A.D., Diller L.R., et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 2008, 299(11):1315-1319.
19. Salmon A., Amikam D., Sodha N., et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) 2007, 19(7):490-493.
20. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16(1):64-67.
21. Marsh D.J., Coulon V., Lunetta K.L., et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998, 7(3):507-515.
22. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000, 37(11):828-830.
23. Hobert J.A., Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009, 11(10):687-694.
24. Brownstein M.H., Wolf M., Bikowski J.B. Cowden's disease: a cutaneous marker of breast cancer. Cancer 1978, 41(6):2393-2398.
25. Nelen M.R., Kremer H., Konings I.B., et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999, 7(3):267-273.
26. Schrager C.A., Schneider D., Gruener A.C., et al. Clinical and pathological features of breast disease in Cowden's syndrome: an under-recognized syndrome with an increased risk of breast cancer. Hum Pathol 1998, 29(1):47-53.
27. Nelson H.D., Fu R., Griffin J.C., et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009, 151(10):703-715.
28. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71.
29. Wooster R., Neuhausen S.L., Mangion J., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265(5181):2088-2090.
30. Gudmundsdottir K., Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25(43):5864-5874.
31. Malone K.E., Daling J.R., Doody D.R., et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006, 66(16):8297-8308.
32. Roa B.B., Boyd A.A., Volcik K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14(2):185-187.
33. Robson M., Dabney M.K., Rosenthal G., et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1997, 1(1):47-51.
34. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
35. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11(14):5175-5180.
36. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25(11):1329-1333.
37. Begg C.B., Haile R.W., Borg A., et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008, 299(2):194-201.
38. Gayther S.A., Warren W., Mazoyer S., et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995, 11(4):428-433.
39. Gayther S.A., Mangion J., Russell P., et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997, 15(1):103-105.
40. Antoniou A.C., Spurdle A.B., Sinilnikova O.M., et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82(4):937-948.
41. Panchal S.M., Ennis M., Canon S., et al. Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet 2008, 9:116.
42. Palma M.D., Domchek S.M., Stopfer J., et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 2008, 68(17):7006-7014.
43. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351(5):427-437.
44. Kuhl C.K., Schrading S., Leutner C.C., et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005, 23(33):8469-8476.
45. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365(9473):1769-1778.
46. Andrieu N., Easron D.F., Chang-Claude J., et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 2006, 24(21):3361-3366.
47. Narod S.A., Lubinshi J., Ghadirian P., et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006, 7(5):402-406.
48. Goldfrank D., Chuai S., Bernstein J.L., et al. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 2006, 15(11):2311-2313.
49. Berrington de Gonzalez A., Berg C.D., Visvanathan K., et al. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009, 101(3):205-209.
50. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
51. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97(22):1652-1662.
52. Vogel V.G., Constantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295(23):2727-2741.
53. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286(18):2251-2256.
54. Gronwald J., Tung N., Foulkes W.D., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006, 118(9):2281-2284.
55. Narod S.A., Dube M.P., Klijn J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002, 94(23):1773-1779.
56. Whittemore A.S., Balise R.R., Pharoah P.D., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004, 91(11):1911-1915.
57. Brohet R.M., Goldgar D.E., Easton D.F., et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007, 25(25):3831-3836.
58. Haile R.W., Thomas D.C., McGuire V., et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1863-1870.
59. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346(21):1616-1622.
60. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346(21):1609-1615.
61. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005, 23(30):7491-7496.
62. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006, 296(2):185-192.
63. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009, 101(2):80-87.
64. Domchek S.M., Friebel T.M., Neuhausen S.L., et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006, 7(3):223-229.
65. Kauff N.D., Domchek S.M., Friebel T.M., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008, 26(8):1331-1337.
66. Parker W.H., Broder M.S., Chang E., et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009, 113(5):1027-1037.
67. Rocca W.A., Grossardt B.R., de Andrade M., et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006, 7(10):821-828.
68. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005, 23(31):7804-7810.
69. Eisen A., Lubinski J., Gronwald J., et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008, 100(19):1361-1367.
70. Madalinska J.B., van Beurden M., Bleiker E.M., et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006, 24(22):3576-3582.
71. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93(21):1633-1637.
72. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345(3):159-164.
73. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22(6):1055-1062.
74. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22(12):2328-2335.
75. Graeser M.K., Engel C., Rhiem K., et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009, 27(35):5887-5892.
76. Rennert G., Bisland-Naggan S., Bernett-Griness O., et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007, 357(2):115-123.
77. Bordeleau L., Panchal S., Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 2010, 119(1):13-24.
78. Tutt A., Ashworth A. Can genetic testing guide treatment in breast cancer?. Eur J Cancer 2008, 44(18):2774-2780.
79. Byrski T., Gronwald J., Huzarski T., et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008, 108(2):289-296.
80. Byrski T., Huzarski T., Dent R., et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009, 115(2):359-363.
81. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
82. Audeh M.W., Penson R.T., Friedlander M., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009, 27(15S):277s.
83. Tutt A., Robson M., Garber J.E., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27(15S):7s.
84. O'Shaughnessy O.C., Pippen J., Yoffe M., et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer: results of a randomized trial. J Clin Oncol 2009, 27(15s):6s.
85. Howlett N.G., Taniguchi T., Olson S., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297(5581):606-609.